Informed prostate cancer risk-adjusted testing: a new paradigm

BJU Int. 2012 Dec:110 Suppl 4:30-4. doi: 10.1111/j.1464-410X.2012.11621.x.

Abstract

• Currently there is significant confusion and polarisation about prostate cancer screening for both patients and physicians alike. • We propose a risk-adjusted testing programme, which would lead to fewer patients who need to be tested and treated to save a life and also eliminate inappropriate prostate-specific antigen testing in the elderly and patients with severe co-morbidities where there is no clear benefit.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / blood
  • Early Detection of Cancer / methods*
  • Global Health
  • Humans
  • Incidence
  • Male
  • Mass Screening*
  • Prostate-Specific Antigen / blood*
  • Prostatic Neoplasms* / blood
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / epidemiology

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen